Tumor Necrosis Factor β
human, recombinant, E. coli
For in vitro use only!
Shipping: shipped at ambient temperature
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 18.6 kDa
Accession number: P01374
Accession number: P01374
Purity: > 95 % (SDS-PAGE)
Solubility: It is recommended to reconstitute the lyophilised TNF-β in sterile bidest H2O not less than 100 μg/ml. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Activity: ED50: < 0.05 ng/ml, determined by the cytolysis of murine L929 cells in the presence of Actinomycin D corresponding to a Specific Activity of 2 x107 IU/mg.
As well as regulating cell proliferation and apoptosis, the TNF-TNF Receptor system also plays an important role in the control of lymphoid organogenesis. Furthermore, TNF-α and TNF-β induce MHC class I and class II antigens as well as chemokines, and play a critical role in cell-cell interactions and lymphocyte trafficking. TNFs are also known to be involved in the defense against pathogens and in the induction of inflammatory and autoimmune diseases. TNF-β enhances cytotoxic responses against normal and transformed cell types. TNF would therefore appear to be essential in the regulation and maintenance of immune system homeostasis under normal and pathological conditions. Recombinant human TNF-β (Lymphotoxin) produced in E. coli is a single, non-glycosylated, polypeptide chain containing 171 amino acids and having a molecular mass of 18.6 kDa. Recombinant human Tumor Necrosis Factor-β is purified by standard chromatographic techniques.
Amino Acid Sequence: MLPGVGLTPS AAQTARQHPK MHLAHSTLKP AAHLIGDPSK QNSLLWRANT DRAFLQDGFS LSNNSLLVPT SGIYFVYSQV VFSGKAYSPK ATSSPLYLAH EVQLFSSQYP FHVPLLSSQK MVYPGLQEPW LHSMYHGAAF QLTQGDQLST HTDGIPHLVL SPSTVFFGAF AL
Bogunia-Kubik (2004) Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of posttransplant complications in recipients of allogeneic hematopoietic stem cell transplants. Arch. Immunol. Ther. Exp. (Warsz) 52:240.
Parks et al. (2004) Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum. Immunol. 65:622.
Kahlke et al. (2004) Are postoperative complications genetically determined by TNF-beta NcoI gene polymorphism? Surgery 135:365.
Goyal et al. (2004) Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J. Med. Virol. 72:60.
Um et al. (2003) TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction. J. Mol. Neurosci. 21:167.
Holzer et al. (2003) Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumours. Anticancer Res. 23:3057.
Reddy et al. (2001) IL-2-induced tumor necrosis factor (TNF)-beta expression: further analysis in the IL-2 knockout model, and comparison with TNF-alpha, lymphotoxin-beta, TNFR1 and TNFR2 modulation. Int. Immunol. 13:135.